The recommendations the InfantRisk Center provides are not meant to replace medical advice from your physician. The ultimate decision to breastfeed while taking medications should be based on an informed decision including available data, discussions between a mother, her physician, and the infants' pediatrician. The decision to take medications during pregnancy should be based available data and a discussion between a mother and her OB/GYN.
To ask a question, Create an Account or Login.
"There were no detectable congenital anomalies in 11 births exposed to zolpidem during the first trimester of gestation.[1] There is one case of an infant whose mother took zolpidem in combination with fluvoxamine and meprobamate in the first five weeks of pregnancy; The infant was born with hydrocephaly, right diaphragmatic hernia, and agenesis of the corpus callosum.[2] However, no conclusions can be made on the basis of this single report. [4] One case reported transplacental transfer of zolpidem.[3] A 30-year-old woman who had a history of zolpidem abuse delivered spontaneously at 38 weeks of gestation. It was estimated to be at least 1000 mg over at least 1 month; however, the total fetal exposure to zolpidem was unknown. In the blood cord, the concentration of zolpidem was 41 ng/mL. The neonate was active and alert, and no withdrawal symptoms were noted despite the presence of zolpidem in the cord blood sample.[3] There are no additional data available on the behavior of neonates born to women on zolpidem.[4] However, experience with other sedative-hypnotics suggest that flaccidity or withdrawal symptoms may occur.[4] Furthermore, neonates born to women on benzodiazepines may show temperature instability; whether such effects will occur after zolpidem exposure is unknown. [4]" (Medications and Mothers' Milk database, Dr Thomas Hale PhD).
1.## Wilton LV, Pearce GL, Martin RM et al: The outcomes of pregnancy women exposed to newly marketed drugs in general practice n England. Br J Obstet Gynaecol 105:882-889, 1998.
2.## McElhatton PR, Garbis HM, Elefant E et al: The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepres ants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 10:285-294, 199 .
3.## Askew JP: Zolpidem addiction in a pregnant woman with a history of second-trimester bleeding. Pharmacotherapy 2007; 27:306- .
4.##The REPROTOX® System. Georgetown University Medical Center and Reproductive Toxicology Center, Columbia Hospital for Women Medical Center, Washington, D.C. (electronic version). Thomson Reuters, Greenwood Village, Colorado, USA. Available at: [url]http://csi.micromedex.com[/url] (May/28/2010).
Comment